ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.

ABSTRACT:

Background

Cisplatin-radiotherapy is a preferred standard for locally advanced, head and neck squamous cell carcinoma (HNSCC). However, the cisplatin-attributable survival benefit is small and toxicity substantial. A biomarker of cisplatin resistance could guide treatment selection and spare morbidity. The ERCC1-XPF nuclease is critical to DNA repair pathways resolving cisplatin-induced lesions.

Methods

In a phase II trial, patients with untreated Stage III-IVb HNSCC were randomised to cisplatin-radiotherapy with/without erlotinib. Archived primary tumours were available from 90 of 204 patients for this planned substudy. Semi-quantitative ERCC1 protein expression (H-score) was determined using the FL297, 4F9, and 8F1 antibodies. The primary analysis evaluated the relationshi

SUBMITTER: Bauman JE 

PROVIDER: S-EPMC3798971 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature